The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BRAF variants and oncogenic fusions to define sporadic MMR-deficient colorectal cancer subtypes.
 
Somer Abdelfattah
No Relationships to Disclose
 
Guilherme Harada
Speakers' Bureau - AstraZeneca; Lilly; Merck; MSD; Pfizer
 
Shrey Patel
No Relationships to Disclose
 
Oliver Artz
No Relationships to Disclose
 
Rona Yaeger
Honoraria - Zai Lab
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo/UCB Japan (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Paul Johannet
No Relationships to Disclose
 
Emily Harrold
Consulting or Advisory Role - Pfizer
 
Henry S. Walch
No Relationships to Disclose
 
Guillem Argiles
Honoraria - Gadeta
Consulting or Advisory Role - Amgen; Bayer
Travel, Accommodations, Expenses - Bayer; Roche; SERVIER
 
Benoit Rousseau
Consulting or Advisory Role - Bayer; NeoPhore; Roche
Speakers' Bureau - Bayer; Gilead Sciences
Research Funding - Roche (Inst)
Patents, Royalties, Other Intellectual Property - Methods and composition for cancer immunotherapy
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; SERVIER
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Neurogene (I); Novartis (I); Optos (I); Outlook Therapeutics (I); Regeneron (I)
 
Andrea Cercek
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Seagen
Patents, Royalties, Other Intellectual Property - Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Neoadjuvant PD1 blockade in mismatch repair deficient solid tumors (Inst)
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Inspirna
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Master Clinician Alliance; Merck; Michael J. Hennessy Associates; Peerview; Research to Practice
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Geneos; GlaxoSmithKline; Guardant Health; Imedex; Imugene; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Phanes Therapeutics; Research to Practice; Rgenix; Seagen; Silverback Therapeutics; Zymeworks
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice
 
Alexander E. Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Luis A. Diaz
Leadership - Epitope Diagnostics; Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Epitope Diagnostics; Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Other Relationship - Blackstone; Innovatus Capital Partners
 
Michael Bonner Foote
No Relationships to Disclose